Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierFounded with the mission to remove the fear of the unknown through powerful and accessible smNGS-based diagnostics, we have swiftly transitioned from an R&D-focused company to a proven commercial organization. In 2019, we launched our first prenatal product, UNITY. UNITY is the first NIPT that uses cfDNA to provide fetal risk assessment for recessive conditions such as sickle cell disease and cystic fibrosis without requiring a paternal sample or invasive procedures such as amniocentesis.
In the company’s own words · 10-K filed Mar 11, 2026 · SEC EDGAR
Business segments
Q1 2026 · $108.4MThe company’s own SEC segment disclosure.
- Prenatal$96.5M89%
- Oncology$10.7M10%
- Clinical Trial Support And Other Services$1.1M1%
BillionToOne, Inc. (BLLN) reported revenue of $108M in Q1 2026 (quarter ended March 31, 2026), up 84% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $18M (17% of revenue). For the full year FY2025, revenue was $305M (+100% year on year) and net income $7.5M. Its largest product in 2026-Q1 was Prenatal at $97M, 89% of the disclosed total, just ahead of Oncology at 9.9%.
Raw charts
7 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #14 of 29 by Smart Score